臺灣博碩士論文加值系統

研究目的
透析管路相關血流感染是院內感染花費金額最高的感染，對於透析病人和醫療系統有顯著的影響，本研究目的是探討使用抗生素管路容易是否可以預防透析管路相關血流感染。
方法
本研究為一系統性回顧與統合分析，搜尋Pubmed、Cochrane Central Register of Controlled Trials及Scopus，收納研究類型為隨機分派研究，由兩位作者分別以Cochrane risk of bias tool評估研究品質。研究終點為管路相關血流感染(Catheter related blood stream infection, CLABSI)、管路失效(catheter failure)、導管相關菌血症(catheter related bacteremia, CRB)、導管出口感染(exit site infection, ESI)。
分析使用隨機效應(random-effects)統合分析，異質性以Cochran Q test 及 I-2 statistics 評估，發表性誤差以漏斗圖、Egger’s test及trim and fill test評估。以隨機效應統合性迴歸分析（meta-regression）分析導管留置時間與管路相關血流感染的關聯，次群組分析以抗生素導管溶液內的抗凝血劑分為肝素組與非肝素組，敏感性分析探討符合National Kidney Foundation’s Kidney Disease Outcomes and Quality Initiative (NKF-K/DOQI)預防管路感染措施是否影響抗生素管路預防管路相關血流感染。
結果
本研究共收納15篇符合收納條件的隨機分派研究。在管路相關血流感染方面，抗生素導管顯著降低發生風險(rate ratio [RR], 0.36 [95% CI 0.27-0.48])，抗生素管路組的管路失敗風險較低但未達顯著標準(RR, 0.89 [95% CI 0.62-1.29])。在統合性迴歸分析中，導管留置時間與管路相關血流感染有顯著關聯(P=0.04)，導管留置時間增加，發生管路相關血流感染的風險增加。次群組分析中非肝素組有較低的管路相關血流感染風險，且兩組異質性檢定達顯著標準(P=0.033)。敏感性分析中在符合NKF-K/DOQI預防管路感染措施的研究中，抗生素管路仍顯著降低管路相關血流感染的發生率(RR, 0.22 [95% CI 0.12-0.43])。漏斗圖及Egger’s test顯示有發表性誤差(Egger’s test, P=0.05)，但trim and fill test並未改變分析結果。
結論
抗生素導管溶液可顯著降低透析導管發生管路相關血流感染風險，統合回歸中導管留置時間與管路相關血流感染有顯著關聯，導管留置時間愈短，抗生素導管溶液預防血流感染的成效愈高，因此抗生素管路溶液可考慮使用在暫時性留置的透析導管。

Background
Central line-associated blood stream infection (CLABSI) is a severe complication in hemodialysis patients. Although the application of an antibiotic lock solution can reduce CLABSI risk, the practice guidelines limit its use if CLABIS recurs despite application of standard preventive measures in long-term catheter users. Therefore, we evaluated whether catheter duration and guideline-recommended preventive measure affect the efficacy of an antibiotic lock solution for CLABSI prevention.
Methods
We searched PubMed, the Cochrane Central Register of Controlled Trials, and Scopus from their inception to July 2016 and included randomized controlled trials; we evaluated their methodological quality levels using the Cochrane Risk of Bias Tool. Study outcomes were incidence rate ratio of CLABSI, exit-site infection, catheter-related bacteremia (CRB), and catheter failure. Random effect models were used for all meta-analyses. Publication bias was evaluated using funnel plots, the Egger test, and the trim and fill method. We used random-effects meta-regression to investigate the effect of catheter duration on the efficacy of antibiotic lock for CLABSI prevention. Subgroup analysis was stratified by antithrombotic agents.
Results
In total, 993 citations were evaluated, and 15 studies were included in the meta-analysis. Our meta-analysis showed that antibiotic lock solution application reduced CLABSI risk by 63% (rate ratio [RR], 0.37 [95% CI 0.28–0.48]). Exit-site infection, catheter failure, and CRB also demonstrated risk reduction. In meta-regression, we found correlation between catheter efficacy for CLABSI prevention and catheter duration (P=0.04).
Conclusion
Antibiotic lock solutions can significantly reduce risk of CLABSI; in addition, the correlation between catheter duration and efficacy of antibiotic lock solution is significant. Efficacy of antibiotic lock of CLABSI prevention decreases as catheter duration is longer; therefore, antibiotic lock solution should be considered in temporary catheter users.

口試委員會審定書 i
中文摘要 ii
Abstract iv
實習單位簡介 1
Chapter 1: Introduction 4
Chapter 2: Methods 6
Chapter 3: Result 10
Chapter 4: Discussion 12
Chapter 5: Conclusion 15
Reference 16
Appendix 1 20
Appendix 2 31

1.Santoro A, Canova C, Freyrie A, Mancini E. Vascular access for hemodialysis. J Nephrol. 2006;19(3):259-264.
2.Lee T, Shingarev R. Vascular Access in Hemodialysis. In: Magee CC, Tucker JK, Singh AK, eds. Core Concepts in Dialysis and Continuous Therapies. Boston, MA: Springer US; 2016:71-91.
3.Steven J Bander, Steve J Schwab, Karen Woo. Central catheters for acute and chronic hemodialysis access. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on March 23, 2017.).
4.Vital signs: central line-associated blood stream infections--United States, 2001, 2008, and 2009. MMWR. Morbidity and mortality weekly report. 2011;60(8):243-248.
5.Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA internal medicine. 2013;173(22):2039-2046.
6.Guerin K, Wagner J, Rains K, Bessesen M. Reduction in central line-associated bloodstream infections by implementation of a postinsertion care bundle. American journal of infection control. 2010;38(6):430-433.
7.Kim JS, Holtom P, Vigen C. Reduction of catheter-related bloodstream infections through the use of a central venous line bundle: epidemiologic and economic consequences. American journal of infection control. 2011;39(8):640-646.
8.Tang HJ, Lin HL, Lin YH, Leung PO, Chuang YC, Lai CC. The impact of central line insertion bundle on central line-associated bloodstream infection. BMC infectious diseases. 2014;14:356.
9.Zacharioudakis IM, Zervou FN, Arvanitis M, Ziakas PD, Mermel LA, Mylonakis E. Antimicrobial lock solutions as a method to prevent central line-associated bloodstream infections: a meta-analysis of randomized controlled trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014;59(12):1741-1749.
10.Yahav D, Rozen-Zvi B, Gafter-Gvili A, Leibovici L, Gafter U, Paul M. Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008;47(1):83-93.
11.O''Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011;52(9):e162-193.
12.Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Vol 3392009.
13.Control CfD, Prevention. Bloodstream infection event (central line-associated bloodstream infection and non-central line-associated bloodstream infection). January; 2015.
14.Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration''s tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed.). 2011;343:d5928.
15.Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clinical infectious diseases. 2009;49(1):1-45.
16.Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. 2011.
17.DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986;7(3):177-188.
18.Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002;21(11):1539-1558.
19.Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Vol 3151997.
20.Duval S, Tweedie R. A Nonparametric "Trim and Fill" Method of Accounting for Publication Bias in Meta-Analysis. Journal of the American Statistical Association. 2000;95(449):89-98.
21.Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Statistics in medicine. 2002;21(11):1559-1573.
22.Beathard GA. Catheter management protocol for catheter-related bacteremia prophylaxis. Seminars in dialysis. 2003;16(5):403-405.
23.Henry Ford Health System. Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- 2016 October 23.] Available from: https://clinicaltrials.gov/ct2/show/study/NCT00294502 NLM Identifier:NCT00294502.
24.Dogra GK, Herson H, Hutchison B, et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. Journal of the American Society of Nephrology : JASN. 2002;13(8):2133-2139.
25.McIntyre CW, Hulme LJ, Taal M, Fluck RJ. Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney international. 2004;66(2):801-805.
26.Silva J, Teixeira e C, Baptista A, Ramos A, Ponce P. Catheter-related bacteremia in hemodialysis: which preventive measures to take? Nephron. Clinical practice. 2008;110(4):c251-257.
27.Zhang P, Yuan J, Tan H, Lv R, Chen J. Successful prevention of cuffed hemodialysis catheter-related infection using an antibiotic lock technique by strictly catheter-restricted antibiotic lock solution method. Blood purification. 2009;27(2):206-211.
28.Filiopoulos V, Hadjiyannakos D, Koutis I, et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. American journal of nephrology. 2011;33(3):260-268.
29.Moran J, Sun S, Khababa I, Pedan A, Doss S, Schiller B. A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2012;59(1):102-107.
30.Saxena AK, Panhotra BR. The impact of catheter-restricted filling with cefotaxime and heparin on the lifespan of temporary hemodialysis catheters: a case controlled study. Journal of nephrology. 2005;18(6):755-763.
31.Saxena AK, Panhotra BR, Sundaram DS, Morsy MN, Al-Ghamdi AM. Enhancing the survival of tunneled haemodialysis catheters using an antibiotic lock in the elderly: a randomised, double-blind clinical trial. Nephrology (Carlton, Vic.). 2006;11(4):299-305.
32.Saxena AK, Panhotra BR, Al-hafiz AA, Sundaram DS, Abu-Oyun B, Al Mulhim K. Cefotaxime-heparin lock prophylaxis against hemodialysis catheter-related sepsis among Staphylococcus aureus nasal carriers. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2012;23(4):743-754.
33.Bleyer AJ, Mason L, Russell G, Raad, II, Sherertz RJ. A randomized, controlled trial of a new vascular catheter flush solution (minocycline-EDTA) in temporary hemodialysis access. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America. 2005;26(6):520-524.
34.Campos RP, do Nascimento MM, Chula DC, Riella MC. Minocycline-EDTA lock solution prevents catheter-related bacteremia in hemodialysis. Journal of the American Society of Nephrology : JASN. 2011;22(10):1939-1945.
35.Nori US, Manoharan A, Yee J, Besarab A. Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2006;48(4):596-605.
36.Sofroniadou S, Revela I, Smirloglou D, et al. Linezolid versus vancomycin antibiotic lock solution for the prevention of nontunneled catheter-related blood stream infections in hemodialysis patients: a prospective randomized study. Seminars in dialysis. 2012;25(3):344-350.
37.Kim SH, Song KI, Chang JW, et al. Prevention of uncuffed hemodialysis catheter-related bacteremia using an antibiotic lock technique: a prospective, randomized clinical trial. Kidney international. 2006;69(1):161-164.
38.Ishani A, Collins AJ, Herzog CA, Foley RN. Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study. Kidney international. 2005;68(1):311-318.
39.Flanagan ME, Welsh CA, Kiess C, Hoke S, Doebbeling BN. A national collaborative for reducing health careassociated infections: current initiatives, challenges, and opportunities. American journal of infection control. 2011;39(8):685-689.
40.Oliver MJ, Callery SM, Thorpe KE, Schwab SJ, Churchill DN. Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: a prospective study. Kidney international. 2000;58(6):2543-2545.
41.Weijmer MC, van den Dorpel MA, Van de Ven PJG, et al. Randomized, Clinical Trial Comparison of Trisodium Citrate 30% and Heparin as Catheter-Locking Solution in Hemodialysis Patients. Journal of the American Society of Nephrology. 2005;16(9):2769-2777.
42.Percival SL, Kite P, Eastwood K, et al. Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm. Infection Control. 2005;26(06):515-519.